Topiramate for Binge Eating: How It Works & Side Effects

Topiramate consistently reduces binge eating episodes in clinical trials, often more effectively than any other medication studied for binge eating disorder. A network meta-analysis with high-certainty evidence ranked it first among pharmacotherapies for both reducing binge frequency and achieving remission. But topiramate was originally developed for epilepsy, and its side effect profile reflects that origin in ways that matter for anyone considering it.

How Topiramate Affects the Brain and Appetite

Topiramate does not work through a single clean mechanism. It acts on several brain systems at once, which is part of why it influences binge eating from multiple angles and also why it produces such a wide range of side effects.

One of the more revealing findings comes from research on appetite-regulating brain circuits. Topiramate strongly inhibits a group of neurons called NPY/AgRP neurons, which are among the brain’s most powerful hunger-promoting cells. When these neurons fire, they drive eating behavior. Topiramate quiets them. Interestingly, it does this not through the mechanism researchers initially expected. Topiramate is well known for enhancing GABA activity (a calming neurotransmitter), but its suppression of these hunger neurons works through a different pathway involving GABA-B receptors and potassium channels rather than the GABA-A receptors typically associated with the drug.

Beyond direct appetite suppression, topiramate also dampens glutamate signaling, an excitatory brain chemical linked to impulsive behavior and mood instability. Some researchers have proposed that this glutamate-blocking effect helps reduce the impulsive, compulsive quality of binge episodes, making it easier for people to resist the urge to eat past the point of fullness. There is also evidence that topiramate may help stabilize mood and reduce impulsiveness more broadly, though this indication remains debated.

The drug also appears to shift hormonal signals related to body weight. In a study of prepubertal children with epilepsy, topiramate lowered body mass index, fasting insulin-to-glucose ratios, cortisol, and leptin levels over six months, while glucose, ghrelin, neuropeptide-Y, and insulin levels did not change significantly.

The drop in leptin is worth noting. Leptin normally rises with body fat and signals the brain to reduce appetite. As topiramate causes weight loss, leptin levels fall because there is less fat tissue producing it. The cortisol reduction could also play a role in binge eating, since elevated cortisol is linked to stress-driven eating. No single mechanism fully explains the drug’s effects on binge eating, but the combined action on hunger neurons, glutamate signaling, and metabolic hormones paints a picture of a drug that hits the problem from several directions simultaneously.

What the Clinical Trials Show

The first major randomized controlled trial for binge eating disorder specifically tested topiramate against placebo in people who also had obesity. Participants on topiramate saw a 94% reduction in binge frequency, compared to 46% in the placebo group. Reductions in the number of binge days were nearly identical: 93% versus 46%. The drug also produced meaningful improvements in body weight, BMI, and scores on clinical severity and obsessive-compulsive eating behavior scales.

⁴

A systematic review looking across multiple controlled trials in both binge eating disorder and bulimia nervosa found a consistent pattern. Short-term topiramate treatment reduced binge episodes by about five per week compared to roughly three per week in placebo groups, with similar advantages in binge days. Weight loss was also substantial: people on topiramate lost an average of about 4.6 kilograms, while those on placebo lost only about half a kilogram.

⁵

That said, the same review noted that high dropout rates and small sample sizes in several of the trials limit how confidently these numbers can be generalized. This is a common problem in eating disorder research, where participants may leave studies because of side effects, because they feel better and stop treatment, or because of the psychological burden of the disorder itself. The results are encouraging, but they come with the usual caveats of a field where large, long-duration trials are scarce.

How It Compares to Other Medications

Lisdexamfetamine (sold as Vyvanse) is the only medication with FDA approval specifically for binge eating disorder. So where does topiramate fit? The comparison data are actually quite favorable for topiramate. A network meta-analysis covering the available evidence with high-certainty ratings found that topiramate showed the greatest efficacy for reducing binge eating episodes and the highest odds of achieving remission, followed by lisdexamfetamine and then dasotraline.

⁶

A separate network meta-analysis confirmed that topiramate and lisdexamfetamine reduced binge eating frequency by similar amounts compared to placebo. When it came to weight loss, topiramate had a slight edge, producing about 5.5 kilograms of weight loss versus 4.6 kilograms for lisdexamfetamine.

⁷

Despite this evidence, topiramate is not FDA-approved for binge eating disorder, and treatment guidelines generally do not provide strong recommendations for medications beyond lisdexamfetamine.

⁸

Addiction and eating disorder specialists have increasingly considered topiramate a reasonable second-line option, particularly for people who cannot tolerate stimulant medications or who have co-occurring conditions like alcohol use disorder where topiramate may offer dual benefits.

⁹

There is also preliminary evidence that a combination of phentermine and extended-release topiramate (already marketed together for weight loss) may help reduce both binge eating symptoms and weight in people with obesity and binge eating disorder.

¹⁰

Cognitive and Language Side Effects

This is the side effect category that makes topiramate distinctive and, for many people, the deciding factor in whether they stay on it. Topiramate has earned the informal nickname “dopamax” among patients because of its effects on thinking and word retrieval. The experience often feels like a fog settling over language: you know the word you want but cannot find it, sentences come out jumbled, and processing speed slows down.

Research backs up these reports. One study found a clear relationship between topiramate blood levels and impairment on verbal fluency during a picture description task, on paragraph recall tests, and on reaction time during working memory tasks. The higher the drug concentration, the worse performance got.

¹¹

A broader review of the evidence estimated that up to about one in ten patients report cognitive side effects. These problems tend to appear early, usually within the first six weeks, and are dose-dependent. Using lower doses, slower titration schedules, and topiramate as the only brain-active medication (rather than combining it with other anticonvulsants) all reduce the risk. The severity is generally mild to moderate, and language problems, particularly word-finding difficulty, are the most consistently documented issue. Beyond language, the evidence for other cognitive domains is less clear-cut.

¹²

For someone whose work depends heavily on verbal fluency, like teaching, public speaking, writing, or customer-facing roles, even mild word-finding problems can feel disproportionately disruptive. This is worth discussing honestly with a prescriber before starting treatment, because the cognitive effects are the most common reason people discontinue topiramate outside of formal clinical trials.

Kidney Stones and Metabolic Acidosis

Topiramate inhibits an enzyme called carbonic anhydrase, and this creates a chain reaction in the kidneys. The drug makes your blood more acidic (metabolic acidosis) and changes the chemical composition of your urine, specifically by reducing citrate levels and raising urine pH. Citrate normally acts as a natural inhibitor of stone formation, so when it drops, the risk of developing calcium phosphate kidney stones goes up.

¹³

A case study of a patient on long-term topiramate treatment illustrated this progression clearly: chronic metabolic acidosis developed, followed by kidney stone formation.

¹⁴

Staying well hydrated is the most straightforward way to reduce this risk. Some clinicians also monitor blood bicarbonate levels periodically, especially in people on higher doses or those with a personal or family history of kidney stones. If you have ever had a kidney stone before, that history is worth bringing up before starting topiramate, because the drug meaningfully shifts the biochemistry in a direction that favors stone formation.

The Carbonation Effect and Other Sensory Surprises

One of the stranger and less-discussed side effects of topiramate is that it can change how carbonated drinks taste. Because topiramate inhibits carbonic anhydrase, the same enzyme involved in the kidney effects described above, it interferes with the chemical process that gives carbonation its fizzy, slightly stinging sensation on the tongue. The result is that beer, soda, and sparkling water taste flat. A case report described a patient who experienced this immediately after starting topiramate and found that the effect persisted for the entire 12 months she remained on the drug, though drinking through a straw slightly reduced the sensation of flatness.

¹⁵

This is not medically dangerous, but it catches people off guard, and for some it is more annoying than you might expect. If sparkling water is your primary hydration method, for instance, or if you enjoy beer socially, you will want to know this going in. The mechanism is the same carbonic anhydrase inhibition behind the kidney stone risk and metabolic acidosis, so the flat-tasting soda is essentially a harmless surface marker of a deeper enzymatic change.

Tingling in the hands and feet (paresthesia) is another common side effect that relates to the drug’s broad mechanism of action. It is usually mild and often fades over the first few weeks, but some people find it persistent and irritating.

Why Starting Slowly Matters

Topiramate is one of those medications where the path to the target dose can determine whether someone stays on it. Most side effects are front-loaded, appearing during the titration phase when doses are being increased, and a slower ramp-up reduces the chance of problems.

A clinical trial comparing titration schedules found that increasing the dose by 50 mg per week (instead of a faster schedule) significantly reduced the number of side effects that led to dose changes, treatment interruptions, or discontinuation.

¹⁶

This aligns with broader pharmacokinetic reviews noting that most dose-limiting adverse events cluster during titration and can be minimized with slower upward adjustments.

¹⁷

In practice, many clinicians start at 25 mg per day and increase by 25 mg weekly or every two weeks, aiming for a range that balances effectiveness against side effects. The target dose for binge eating in the trials varied, but many used doses between 150 and 400 mg per day. Finding the right dose often involves some back-and-forth, particularly because the cognitive side effects are dose-dependent. A person who does fine at 100 mg might notice significant word-finding problems at 200 mg, and the clinical task becomes finding the dose where binge reduction is meaningful but cognition remains acceptable.

Pregnancy and Oral Cleft Risk

This is the most serious safety concern with topiramate and one where the evidence is unusually clear for a drug safety signal. Women who take topiramate during early pregnancy have a significantly elevated risk of having a baby with an oral cleft (cleft lip, cleft palate, or both).

A large pregnancy cohort study found that the risk of oral clefts was about 4.1 per 1,000 births among infants exposed to topiramate, compared to 1.1 per 1,000 in the unexposed group, roughly a threefold increase. The risk was especially pronounced at higher doses: for topiramate monotherapy above 100 mg per day, the risk rose to about five times the background rate.

¹⁸

A pooled analysis from birth defect surveillance programs found a similar signal, with an odds ratio of about 5.4 for cleft lip with or without cleft palate in topiramate-exposed infants. The drug was not associated with an increase in overall major birth defects, but the specific cleft risk was statistically significant.

¹⁹

For context, oral clefts are surgically repairable, and even a fivefold increase over a low baseline rate means the absolute risk is still small in percentage terms. But it is a clearly established, dose-related teratogenic risk. The FDA has placed topiramate in a category reflecting this concern, and in 2024 the agency strengthened its warning language. Anyone who could become pregnant and is considering topiramate should use reliable contraception and discuss the risk explicitly with their prescriber. If you are actively planning a pregnancy, topiramate is generally not the right choice.

Topiramate for Bulimia Nervosa

While binge eating disorder involves recurrent binge episodes without the compensatory behaviors (purging, excessive exercise, fasting) that define bulimia nervosa, topiramate has been studied in both conditions, and the findings in bulimia are worth knowing if you are exploring this medication.

A randomized trial in bulimia found that the mean number of weekly binge and/or purge days dropped by about 45% with topiramate versus roughly 11% with placebo. Purge frequency specifically declined by about 50% on the drug compared to about 22% on placebo. Beyond the behavioral changes, topiramate was also associated with improvements in self-esteem, eating attitudes, anxiety, and body image.

²⁰²¹

The improvement in psychiatric symptoms alongside binge and purge behavior is potentially meaningful. Many people with eating disorders experience pervasive body dissatisfaction and anxiety that standard behavioral interventions address only partially. A medication that simultaneously reduces binge frequency and eases some of the psychological distress surrounding eating could offer a qualitatively different kind of improvement. That said, topiramate is not considered a first-line treatment for bulimia either; selective serotonin reuptake inhibitors and cognitive behavioral therapy remain the standard starting points.

Weight Loss as a Complicated Benefit

Weight loss on topiramate is one of the features that makes it appealing for binge eating disorder, where obesity is common. Across studies, people with binge eating disorder who took topiramate lost substantially more weight than those on placebo, on the order of several kilograms over treatment periods of several months. In the network meta-analysis comparing BED medications, topiramate produced the greatest weight reduction at roughly 5.5 kilograms.

⁷

But in eating disorder treatment, weight loss is not a straightforwardly good thing. For some patients, the weight loss itself can become psychologically reinforcing in unhealthy ways, potentially shifting binge eating toward more restrictive patterns or contributing to an over-focus on the scale. A good clinician prescribing topiramate for BED will monitor not just binge frequency and weight but also the person’s relationship to the weight change. The goal is reduced binge eating and improved quality of life, not weight loss for its own sake. If the medication is primarily serving as a weight-loss tool and binge episodes have not meaningfully changed, that is a signal to reconsider the treatment plan.

There is also the question of what happens when you stop. Long-term data on topiramate for binge eating are limited, and weight regain after discontinuation is common with virtually all weight-loss medications. The evidence for sustained benefit after stopping topiramate has not been established in large trials, so the decision to start the drug should include a realistic conversation about duration of treatment and what comes next.